(Q38105942)

28 August 2017

High-dose cytarabine (HD araC) in the treatment of leukemias: a review (English)

1 reference

28 August 2017

1 reference

1 reference

Nicholas D Reese

1

1 reference

PubMed ID

23666364

28 August 2017

Gary J Schiller

series ordinal

2

1 reference

28 August 2017

1 June 2013

1 reference

Current hematologic malignancy reports

28 August 2017

1 reference

28 August 2017

8

1 reference

28 August 2017

2

1 reference

28 August 2017

141-148

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-013-0156-3

28 August 2017

0 references

cites work

Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

The characteristics and outcome of patients with late relapse acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Biochemical modulation of cytarabine triphosphate by clofarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

The incidence of central nervous system leukemia in adults with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0156-3

High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study

21 January 2018

1 reference

12 December 2020

Natural history of central nervous system acute leukemia in adults

1 reference

12 December 2020

Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells

1 reference

12 December 2020

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

12 December 2020

Cytidine deaminase and the development of resistance to arabinosyl cytosine.

1 reference

12 December 2020

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

1 reference

12 December 2020

FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.

1 reference

12 December 2020

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult

1 reference

12 December 2020

A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.

1 reference

12 December 2020

Clinical pharmacology of l-β-D-arabinofuranosyl cytosine

1 reference

12 December 2020

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

12 December 2020

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

12 December 2020

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

1 reference

12 December 2020

Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis

1 reference

12 December 2020

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy

1 reference

12 December 2020

Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

1 reference

12 December 2020

Treatment of resistant disease

1 reference

12 December 2020

Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma

1 reference

12 December 2020

A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid

1 reference

12 December 2020

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.

1 reference

12 December 2020

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine

1 reference

12 December 2020

Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group

1 reference

12 December 2020

High-dose cytosine arabinoside therapy for refractory leukemia

1 reference

12 December 2020

Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside

1 reference

12 December 2020

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions

1 reference

12 December 2020

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

12 December 2020

Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse

1 reference

12 December 2020

Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C)

1 reference

12 December 2020

10.1007/S11899-013-0156-3

Identifiers

DOI

1 reference

PubMed ID

23666364

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23666364